Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report

Abstract

Angiosarcoma of the face and neck is a rare soft tissue sarcoma with a high degree of malignancy. The current treatment methods mainly rely on a combination of surgery and radiotherapy and/or chemotherapy. However, the options for drug treatment are very limited and surgery can be difficult to carry out due to the location of the tumor, so the efficacy of first-line drugs needs to be constantly explored. A case of angiosarcoma of the head and face diagnosed by biopsy is reported here. The patient received an oral anlotinib hydrochloride capsule once a day (12 mg on days 1 - 14/1 week off for a 21-day cycle) due to the difficulty of surgery. Until now (April, 2020), after 10 months of treatment, the patient’s scalp and facial lesions have gradually reduced and the partial response and progression-free survival of this patient were good, with moderate or tolerable adverse events. This approach provides a new approach for the clinical treatment of malignant angiosarcoma of the face and neck with anlotinib as first-line therapy.

Case Report: Two cases of advanced primary cardiac angiosarcoma treated with anlotinib and a retrospective analysis of the literature

“…As a result, he received monotherapy with anlotinib for 10 months (12 mg/day, D1-14, 21 days per cycle). The lesions on his head and face significantly decreased, and he tolerated the adverse drug reactions well (29). Both of our cardiac angiosarcoma patients received anlotinib treatment for approximately 3 days, leading to a notable decrease in the rapid expansion of pleural and pericardial effusion, as well as swift relief from symptoms like breathing difficulties.…”

The diagnosis and treatment for primary cardiac angiosarcoma with N-ras gene mutation and MSI-L: A case report and review of the literature

“…The results of the postoperative pathological examination confirmed the presence of a malignant tumor originating from the blood vessels, which was consistent with the diagnosis of PCA with lung metastasis. Due to the rarity of this disease, the lack of established treatment protocols and the presence of hemoptysis, targeted therapies commonly used for PCA, such as anlotinib [9][10][11] or pazopanib, [12] were not administered to the patient. Instead, based on the patient's symptoms and a review of relevant literature, we initiated treatment with paclitaxel (with albumin) monotherapy.…”

Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma

“…More trials are being conducted to investigate the efficacy of anlotinib monotherapy, anlotinib plus immunotherapy, and anlotinib plus chemotherapy in advanced sarcomas, particularly soft tissue sarcomas ( 31 ). So far, there have been few reports on the efficacy of anlotinib treatment in ASs, with only a few case reports referring to various lesions in head and neck AS ( 32 ) and cardiac AS ( 33 ) or combined immunotherapy in metastatic primary splenic AS ( 34 ). In the case we present, the patient experienced local recurrence in the ear as well as scalp metastases following surgery.…”